USRE38934E1 - Method and reagents for N-alkylating ureides - Google Patents
Method and reagents for N-alkylating ureides Download PDFInfo
- Publication number
- USRE38934E1 USRE38934E1 US10/375,340 US37534003A USRE38934E US RE38934 E1 USRE38934 E1 US RE38934E1 US 37534003 A US37534003 A US 37534003A US RE38934 E USRE38934 E US RE38934E
- Authority
- US
- United States
- Prior art keywords
- methoxymethyl
- ureide
- acid
- phenyl
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 [1*]C(=O)NC([2*])=O Chemical compound [1*]C(=O)NC([2*])=O 0.000 description 18
- QUJWJONOMVNUAN-UHFFFAOYSA-H C.CC(=O)OSO(C)O.COCOC.COCOSO(C)O.I[V](I)I.I[V]I.[V]I Chemical compound C.CC(=O)OSO(C)O.COCOC.COCOSO(C)O.I[V](I)I.I[V]I.[V]I QUJWJONOMVNUAN-UHFFFAOYSA-H 0.000 description 1
- BGFVURIPTJCJLI-UHFFFAOYSA-N C.CCCC(C)CC Chemical compound C.CCCC(C)CC BGFVURIPTJCJLI-UHFFFAOYSA-N 0.000 description 1
- UFWIBUBEFUNVNI-UHFFFAOYSA-N C=CCC(C)C(C)C Chemical compound C=CCC(C)C(C)C UFWIBUBEFUNVNI-UHFFFAOYSA-N 0.000 description 1
- UTCOVDUOFCJZFL-UHFFFAOYSA-N C=NCOC(N)O[NH+](N)[O-] Chemical compound C=NCOC(N)O[NH+](N)[O-] UTCOVDUOFCJZFL-UHFFFAOYSA-N 0.000 description 1
- UXDIDKSSHYFFFT-UHFFFAOYSA-N CC(C)C(C(C)C)(C(C)C)C(C)C Chemical compound CC(C)C(C(C)C)(C(C)C)C(C)C UXDIDKSSHYFFFT-UHFFFAOYSA-N 0.000 description 1
- BLGVDCMNIAOLHA-UHFFFAOYSA-N CC(C)C(C)Br Chemical compound CC(C)C(C)Br BLGVDCMNIAOLHA-UHFFFAOYSA-N 0.000 description 1
- ZPTWCGXIRULANJ-UHFFFAOYSA-N CCBr.CCCC Chemical compound CCBr.CCCC ZPTWCGXIRULANJ-UHFFFAOYSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N CCC Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- ZRPQYKLJSOLRPZ-UHFFFAOYSA-N CCC(C)(Br)CC Chemical compound CCC(C)(Br)CC ZRPQYKLJSOLRPZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N CCCC Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N CNC Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N CNC(C)=O Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N COC Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- SQCVEQVZGPHNTJ-UHFFFAOYSA-N COCN1C(=O)NC(=O)C(c2ccccc2)(c2ccccc2)C1=O Chemical compound COCN1C(=O)NC(=O)C(c2ccccc2)(c2ccccc2)C1=O SQCVEQVZGPHNTJ-UHFFFAOYSA-N 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N O=C1CC(=O)NC(=O)N1 Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
- C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
Definitions
- the invention relates to a new means for N-alkylating ureides that is higher yielding, more convenient, and safer to use than techniques practiced heretofore.
- This approach is particularly suited to preparing N-(alkoxyalkylene) ureides, which include anti-convulsant drugs of the N-substituted barbituric acid class.
- Ureides are a class of imides of general structure I: Examples, include hypnotics, such as acecarbromal, apronalide, bromisolvalum, capuride, carbromal, and ectylurea; and anticonvulsant drugs such as hydantoins, glutarimides, oxazolidinediones, succinimides, and barbiturates such as barbituric acid (structure II).
- hypnotics such as acecarbromal, apronalide, bromisolvalum, capuride, carbromal, and ectylurea
- anticonvulsant drugs such as hydantoins, glutarimides, oxazolidinediones, succinimides, and barbiturates such as barbituric acid (structure II).
- U.S. Pat. No. 4,628,056 teaches a method of making 1,3 bis(methoxymethyl)-5,5-diphenyl barbituric acid (also called (N,N′-bis(methoxymethyl)-5,5-diphenyl barbituric acid) by dissolving diphenyl barbituric acid in cooled dimethylformamide, adding sodium hydride, then adding chloromethyl methyl ether.
- Chloromethyl methyl ether has been widely used to alkylate with a methoxymethylene function. However, it is highly toxic and regulated as a carcinogen. It is extremely volatile and flammable under exothermic reaction conditions, and alternatives to its use are strongly desirable.
- the invention method avoids the use of volatile, carcinogenic chloromethyl methyl ether, replacing that reagent with a more reactive, less volatile alternative which may be generated in situ (without risk to the operator).
- the invention solves a previously unrecognized problem limiting the applicability of methoxymethanesulfante alkylation to alcohols and amines. Ureides are much less basic than amines, so a different method for oxyalkylation is required.
- This invention differs from the method of Karger et al. by using a ureide, a non-aqueous basic catalyst, and an aprotic solvent, modifications which were not previously known or suggested.
- the inventive method allows use of a variety of sulfonates to prepare a broad variety of oxyalkylated ureides, some not previously known. The simplicity and convenience of the invention provide advantages that were not previously appreciated.
- a method of N-alkoxyalkylating ureides comprises reacting a ureide of structure I with an alkylating agent of structure III in the presence of a basic catalyst in an aprotic reaction medium.
- the alkylating agent III may be combined directly with the ureide, or the method may include reacting in situ a mixed anhydride of acetic acid and a sulfonic acid with a dialkoxymethane to provide the alkylating agent III.
- the method preferably involves isolating the resultant N-alkoxyalkylated ureide.
- the ureide is a 5,5-disubstituted barbituric acid, phenytoin, glutethimide, or ethosuximide.
- the alkylating agent may be methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, or methoxymethyl p-toluenesulfonate.
- the base may be selected from sodium hydride, triethyl amine, and di-isopropyl ethyl amine.
- the process includes the step of reacting a dialkoxymethane and a mixed acetic sulfonic anhyride to produce the resulting ester of the sulfonic acid, that reaction may be carried out in the same vessel as the following reaction with the ureide (done sequentially).
- a preferred process comprises N-alkylating 5,5-diphenyl-barbituric acid with a reagent selected from the group consisting of methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, and methoxymethyl p-toluenesulfonate, in the presence of di-isopropyl ethyl amine and isolating the resultant N,N′-bismethoxymethyl-5,5-diphenyl-barbituric acid.
- a reagent selected from the group consisting of methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, and methoxymethyl p-toluenesulfonate
- the invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenyl-barbituric acid, N-methoxymethyl ethosuximide and N-methoxymethyl glutethimide, methods of making them, and a method comprising administering to a patient an effective amount of a pharmaceutical agent selected from the group consisting of N-methoxymethyl-5,5-diphenyl-barbituric acid, N-methoxymethyl ethosuximide and N-methoxymethyl glutethimide.
- the reagent class which possesses the desirable N-alkylating properties is characterized as compounds of structure III where the R groups are preferably as follows:
- R 3 R 4 R 5 1. methoxymethyl methanesulfonate H H CH 3 2. ethoxymethyl methanesulfonate CH 3 H CH 3 3. benzyloxymethyl methanesulfonate phenyl H CH 3 4. methoxymethyl ethanesulfonate H H C 2 H 3 5. methoxymethyl benzenesulfonate H H phenyl 6. methoxymethyl ⁇ -toluenesulfonate H H tolyl 7. methoxybenzylidene methanesulfonate H phenyl CH 3 8. methoxyethylidene methanesulfonate H CH 3 CH 3 A particularly preferred reagent is methoxymethyl methanesulfonate.
- the ureides which have been shown to be alkylated belong to the family of compounds having structure I: which may be linear (with R 1 and R 2 being alkyl, aryl, or arylakyl), or cyclic (R 1 and R 2 bonded to form a ring).
- Tables 2 and 3 depict ureide drugs.
- the preferred family of reactant ureides is the barbituric acids dissolving at 5, as in structure IV with the R groups preferably being the same or different alkyl or aryl groups, and most preferably with both R groups being phenyl.
- Analogous products resulting from the process of the invention, where 5,5-diphenyl-barbituric acid is a substrate include:
- the N-methoxymethyl derivative of 5,5-diphenylbarbituric acid may be prepared by the process of this invention.
- the substrate 5,5-diphenylbarbituric acid is converted to its di-anion salt with a very strong base (as strong as a hydride, e.g. NaH) and then one equivalent is added of the alkoxy-alkylating agent, reagent 1 of Table 1.
- a very strong base as strong as a hydride, e.g. NaH
- reagent 1 of Table 1 one equivalent is added of the alkoxy-alkylating agent
- N-methoxymethyl-5,5-diphenylbarbituric acid is obtained by optimizing the reaction to favor monosubstitution. For example, an excess of the very strong base NaH is used, greater than two molar equivalents per mole of the ureide.
- the monosubstituted product is separated by chromatography or other conventional methods and may be characterized by melting point and nuclear magnetic resonance.
- stoichiometric amounts of the components are used. That is, for mono-alkylation, the ratio of ureide:alkylating agent:base is about 1:1:2; for di-substitution, the ratio is about 1:2:2, and so on. Different ratios may be appropriate depending on the reaction conditions. A person of ordinary skill will recognize that by varying these ratios, the reaction may proceed faster or slower and have higher or lower yield of end products. For example, as discussed above, mono-substitution of a ureide of the barbituric acid family is favored by using excess base.
- the base may be as strong as sodium hydride or as weak as a tertiary amine.
- the basic catalyst is preferably an amine that does not compete with the substrate ureide (or imide). To this end primary and secondary amine catalysts are excluded. Tertiary amines, which react more slowly with the alkylating species, are preferred to minimize the competing reaction through steric hindrance (branching in the amine substituents). Especially preferred for this attribute are highly hindered amines, such as the readily available amine, ethyl di-isopropyl amine.
- the hindrance inhibits quarternization of the catalyst amine by the alkylating agent in competition with the ureide substrate, while not interfering significantly with ability of the amine to act as a base (accept a proton).
- Useful bases include sodium hydride, potassium hydride, lithium hydride, triethylamine, tri-n-propylamine, and di-isopropyl ethyl amine.
- the solvent is chosen so as not to compete with the substrate and to maximize the rate of alkylation.
- dipolar aprotic solvents such as dimethyl formamide, dimethyl sulfoxide, dimethylacetamide, sulfolane, N-methylpyrrolidione, etc., appears to optimize these attributes. Otherwise, any dipolar aprotic solvent may be selected by the person of ordinary skill so long as the solvent is capable of bringing the reactants into solution.
- the preferred temperature range for the alkylation process is at or near ambient temperature (25 ⁇ 5° C.). Higher temperatures tend to stimulate competitive side-reactions between the alkylating agent and the tertiary amine catalyst (where the latter is being used).
- Yields according to the invention are at least as high as with prior art methods.
- the high yields complement the other advantages of the inventive method including the facts that it is much safer, more convenient, and economical, and allows for ready synthesis of new compounds.
- a preferred embodiment of the inventive alkylation process (which employs the preferred substrate and preferred reagent illustrated above) affords the N,N′ disubstituted barbituric acid depicted as structure V where the R groups are phenyl.
- the alkylation preferably takes place in a solvent which is usually a dipolar aprotic solvent like an N,N′-dialkylamide.
- a solvent which is usually a dipolar aprotic solvent like an N,N′-dialkylamide.
- aprotic solvents may also be employed, so long as they are compatible with the base.
- This alkylating technique is particularly novel and convenient in that the active alkylating species may also be generated in situ by employing precursor substances without isolation of the sulfonate reagent itself.
- Dimethoxymethane (10.85 g) was added at 0° C. to 19.7 g of acetylmethanesulfonate. The reaction was stirred at 25° C. for 2 hours. The resultant solution was then added gradually over 45 minutes to a mixture of 10 g of 5,5-diphenylbarbituric acid and 13.85 g of N,N-diisopropyl ethyl amine in 60 ml of dry dimethylformamide. The resultant reaction mixture was stirred for about 15 minutes and then diluted with 180 ml of 2 N HCl, followed by 300 ml of ethyl acetate.
- Completion of the reaction may be checked using conventional methods such as by TLC on silica (mobile phase chloroform methanol 98:2).
- the reaction mixture is diluted with 360 ml of water and extracted with 480 ml of ethyl acetate.
- the organic layer is separated and washed twice with 150 ml of water.
- the solvent is removed by distillation under reduced pressure in order to obtain crude product.
- the crude product may be purified by crystallization from 4 parts of toluene.
- the mixture is heated to reflux to dissolve and cooled to room temperature. According to HPLC the product of the inventive method has 98-100% purity, and yields of about 60-80% may be expected.
- the monosubstituted methoxymethyl derivative is obtained by optimizing the procedure of Example 1A to favor monosubstitution, using an excess of NaH and one equivalent of alkylating agent per equivalent of ureide.
- the monosubstituted product is separated and characterized.
- the compounds of examples 2-6 have advantageous pharmaceutical properties over a sustained period of time. They may be used to treat mammals including humans for convulsions, seizures, muscle stiffness, nervous strain or anxiety, by administering an effective amount of the compound in a pharmaceutically acceptable carrier to the patient.
Abstract
A method of N-alkoxyalkylating ureides according to the invention comprises reacting a ureide of structure I
with an alkylating agent of structure III
in the presence of a basic catalyst in an aprotic reaction medium. The ureide may be a 5,5-disubstituted barbituric acid, or it may be phenytoin, glutethimide, and ethosuximide. The alkylating agent is an ester of a sulfonic acid. The base may be a hydride or amine. A preferred process comprises N-alkoxyalkylating 5,5-diphenyl-barbituric acid with methoxymethyl methanesulfonate in the presence of di-isopropyl ethyl amine and isolating the resultant N,N′-bismethoxymethyl-5,5-diphenyl-barbituric acid. The invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenylbarbituric acid, N-methoxymethyl ethosuximide, and N-methoxymethyl glutethimide, and a method comprising administering them to a patient.
with an alkylating agent of structure III
in the presence of a basic catalyst in an aprotic reaction medium. The ureide may be a 5,5-disubstituted barbituric acid, or it may be phenytoin, glutethimide, and ethosuximide. The alkylating agent is an ester of a sulfonic acid. The base may be a hydride or amine. A preferred process comprises N-alkoxyalkylating 5,5-diphenyl-barbituric acid with methoxymethyl methanesulfonate in the presence of di-isopropyl ethyl amine and isolating the resultant N,N′-bismethoxymethyl-5,5-diphenyl-barbituric acid. The invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenylbarbituric acid, N-methoxymethyl ethosuximide, and N-methoxymethyl glutethimide, and a method comprising administering them to a patient.
Description
The invention relates to a new means for N-alkylating ureides that is higher yielding, more convenient, and safer to use than techniques practiced heretofore. This approach is particularly suited to preparing N-(alkoxyalkylene) ureides, which include anti-convulsant drugs of the N-substituted barbituric acid class.
The term ureide is used in e.g. Foye, Principles of Medicinal Chemistry, 3d ed. (1990), pp. 164, 179, which is incorporated herein by reference. Ureides are a class of imides of general structure I:
Examples, include hypnotics, such as acecarbromal, apronalide, bromisolvalum, capuride, carbromal, and ectylurea; and anticonvulsant drugs such as hydantoins, glutarimides, oxazolidinediones, succinimides, and barbiturates such as barbituric acid (structure II).
Examples, include hypnotics, such as acecarbromal, apronalide, bromisolvalum, capuride, carbromal, and ectylurea; and anticonvulsant drugs such as hydantoins, glutarimides, oxazolidinediones, succinimides, and barbiturates such as barbituric acid (structure II).
U.S. Pat. No. 4,628,056 teaches a method of making 1,3 bis(methoxymethyl)-5,5-diphenyl barbituric acid (also called (N,N′-bis(methoxymethyl)-5,5-diphenyl barbituric acid) by dissolving diphenyl barbituric acid in cooled dimethylformamide, adding sodium hydride, then adding chloromethyl methyl ether. Chloromethyl methyl ether has been widely used to alkylate with a methoxymethylene function. However, it is highly toxic and regulated as a carcinogen. It is extremely volatile and flammable under exothermic reaction conditions, and alternatives to its use are strongly desirable.
Almost three decades ago, methoxymethyl methanesulfonate was identified as an agent for alkylating some alcohols and amines in a self-catalyzing reaction. Karger et al., J.A.C.S. 91:5663 (1969). With amines, the reaction was complex and led to salts, dimers, and other side products being formed. This method has not been applied to alkylation of ureides, or imides, for which there are major differences in electron availability at nitrogen.
The invention method avoids the use of volatile, carcinogenic chloromethyl methyl ether, replacing that reagent with a more reactive, less volatile alternative which may be generated in situ (without risk to the operator).
The invention solves a previously unrecognized problem limiting the applicability of methoxymethanesulfante alkylation to alcohols and amines. Ureides are much less basic than amines, so a different method for oxyalkylation is required. This invention differs from the method of Karger et al. by using a ureide, a non-aqueous basic catalyst, and an aprotic solvent, modifications which were not previously known or suggested. The inventive method allows use of a variety of sulfonates to prepare a broad variety of oxyalkylated ureides, some not previously known. The simplicity and convenience of the invention provide advantages that were not previously appreciated.
A method of N-alkoxyalkylating ureides according to the invention comprises reacting a ureide of structure I with an alkylating agent of structure III in the presence of a basic catalyst in an aprotic reaction medium. The alkylating agent III may be combined directly with the ureide, or the method may include reacting in situ a mixed anhydride of acetic acid and a sulfonic acid with a dialkoxymethane to provide the alkylating agent III. The method preferably involves isolating the resultant N-alkoxyalkylated ureide.
Preferably, the ureide is a 5,5-disubstituted barbituric acid, phenytoin, glutethimide, or ethosuximide. The alkylating agent may be methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, or methoxymethyl p-toluenesulfonate. The base may be selected from sodium hydride, triethyl amine, and di-isopropyl ethyl amine.
When the process includes the step of reacting a dialkoxymethane and a mixed acetic sulfonic anhyride to produce the resulting ester of the sulfonic acid, that reaction may be carried out in the same vessel as the following reaction with the ureide (done sequentially).
A preferred process comprises N-alkylating 5,5-diphenyl-barbituric acid with a reagent selected from the group consisting of methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, and methoxymethyl p-toluenesulfonate, in the presence of di-isopropyl ethyl amine and isolating the resultant N,N′-bismethoxymethyl-5,5-diphenyl-barbituric acid.
The invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenyl-barbituric acid, N-methoxymethyl ethosuximide and N-methoxymethyl glutethimide, methods of making them, and a method comprising administering to a patient an effective amount of a pharmaceutical agent selected from the group consisting of N-methoxymethyl-5,5-diphenyl-barbituric acid, N-methoxymethyl ethosuximide and N-methoxymethyl glutethimide.
Further objectives and advantages will become apparent from a consideration of the description and examples.
PREFERRED EMBODIMENTS In describing preferred embodiments of the present invention illustrated in the drawings, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected, and it is to be understood that each specific element includes all technical equivalents which operate in a similar manner to accomplish a similar purpose.
The reagent class which possesses the desirable N-alkylating properties is characterized as compounds of structure III
where the R groups are preferably as follows:
where the R groups are preferably as follows:
-
- R3=H, lower alkyl, phenyl, or substituted phenyl
- R4=H, lower alkyl, phenyl, or substituted phenyl
- R5=lower alkyl, phenyl, or substituted phenyl
Particular examples of structures belonging to this class are listed in Table 1:
TABLE 1 | |||||
Compound III | R3 | R4 | R5 | ||
1. | methoxymethyl methanesulfonate | H | H | CH3 |
2. | ethoxymethyl methanesulfonate | CH3 | H | CH3 |
3. | benzyloxymethyl methanesulfonate | phenyl | H | CH3 |
4. | methoxymethyl ethanesulfonate | H | H | C2H3 |
5. | methoxymethyl benzenesulfonate | H | H | phenyl |
6. | methoxymethyl ρ-toluenesulfonate | H | H | tolyl |
7. | methoxybenzylidene methanesulfonate | H | phenyl | CH3 |
8. | methoxyethylidene methanesulfonate | H | CH3 | CH3 |
A particularly preferred reagent is methoxymethyl methanesulfonate.
The ureides which have been shown to be alkylated belong to the family of compounds having structure I:
which may be linear (with R1 and R2 being alkyl, aryl, or arylakyl), or cyclic (R1 and R2 bonded to form a ring). Tables 2 and 3 (taken from Foye et al., Principles of Medicinal Chemistry, 3rd Edition (Lea and Febiger 1990), pp.164 and 179) depict ureide drugs.
which may be linear (with R1 and R2 being alkyl, aryl, or arylakyl), or cyclic (R1 and R2 bonded to form a ring). Tables 2 and 3 (taken from Foye et al., Principles of Medicinal Chemistry, 3rd Edition (Lea and Febiger 1990), pp.164 and 179) depict ureide drugs.
TABLE 2 |
Structure of Anticonvulsant Drugs Containing the Ureide Structure |
|
Class of Compounds |
|
||
Barbiturates |
|
||
Hydantoias |
|
||
Glutarimides |
|
||
Oxazolidipediopes |
|
||
Succinimides |
|
||
TABLE 3 |
Ureide Hypnotics |
|
General Structure |
Generic Name | Chemical Name | R1 | R2 |
Acecarbromal | (1-acetyl)-2-(2- bromo-2-ethylbutyryl) urea | CH3CO | |
Aprohalide | (2-isopropyl-4- pentencyl)urea | H | |
Bromisovalum | (2-bromo-3-methyl- butyryl)urea | H | |
Capuride | (2-ethyl-3-methyl- valeryl)urea | H | |
Carbromal | (2-bromo-2-ethyl- butyryl)urea | H | |
Ectylurea | (2-ethyl-cis- crulonoyl)urea | H | |
Examples of these ureides include those listed above and:
- glutethimide (3-ethyl-3-phenyl-piperidine-2,6-dione)
- phenytoin (5,5-diphenyl-2,4-imidazolidinedione)
- ethosuximide (3-ethyl-3-methyl-2,5-pyrrolidinedione)
- 5,5-diphenylbarbituric acid
- 5-phenyl-5-ethylbarbituric acid
- 5,5-diethylbarbituric acid
The preferred family of reactant ureides is the barbituric acids dissolving at 5, as in structure IV with the R groups preferably being the same or different alkyl or aryl groups, and most preferably with both R groups being phenyl.
Analogous products resulting from the process of the invention, where 5,5-diphenyl-barbituric acid is a substrate, include:
-
- N,N′-bismethoxymethyl derivative using reagent 2 of Table 1.
- N,N′-bismethoxybenzylidene derivative using reagent 7 of Table 1.
- N,N′-bismethoxyethylidene derivative using reagent 8 of Table 1.
- N,N′-bisbenzyloxymethyl derivative using reagent 3 of Table 1.
The N-methoxymethyl derivative of 5,5-diphenylbarbituric acid (Formula IX) may be prepared by the process of this invention.
The substrate 5,5-diphenylbarbituric acid is converted to its di-anion salt with a very strong base (as strong as a hydride, e.g. NaH) and then one equivalent is added of the alkoxy-alkylating agent, reagent 1 of Table 1. N-methoxymethyl-5,5-diphenylbarbituric acid is obtained by optimizing the reaction to favor monosubstitution. For example, an excess of the very strong base NaH is used, greater than two molar equivalents per mole of the ureide. The monosubstituted product is separated by chromatography or other conventional methods and may be characterized by melting point and nuclear magnetic resonance.
The substrate 5,5-diphenylbarbituric acid is converted to its di-anion salt with a very strong base (as strong as a hydride, e.g. NaH) and then one equivalent is added of the alkoxy-alkylating agent, reagent 1 of Table 1. N-methoxymethyl-5,5-diphenylbarbituric acid is obtained by optimizing the reaction to favor monosubstitution. For example, an excess of the very strong base NaH is used, greater than two molar equivalents per mole of the ureide. The monosubstituted product is separated by chromatography or other conventional methods and may be characterized by melting point and nuclear magnetic resonance.
Pharmaceutically-effective salts of the alkylated ureides are also contemplated within the scope of the invention.
In general, stoichiometric amounts of the components are used. That is, for mono-alkylation, the ratio of ureide:alkylating agent:base is about 1:1:2; for di-substitution, the ratio is about 1:2:2, and so on. Different ratios may be appropriate depending on the reaction conditions. A person of ordinary skill will recognize that by varying these ratios, the reaction may proceed faster or slower and have higher or lower yield of end products. For example, as discussed above, mono-substitution of a ureide of the barbituric acid family is favored by using excess base.
For the reaction to proceed a non-aqueous basic catalyst is required. The base may be as strong as sodium hydride or as weak as a tertiary amine. For disubstituted products, the basic catalyst is preferably an amine that does not compete with the substrate ureide (or imide). To this end primary and secondary amine catalysts are excluded. Tertiary amines, which react more slowly with the alkylating species, are preferred to minimize the competing reaction through steric hindrance (branching in the amine substituents). Especially preferred for this attribute are highly hindered amines, such as the readily available amine, ethyl di-isopropyl amine. The hindrance inhibits quarternization of the catalyst amine by the alkylating agent in competition with the ureide substrate, while not interfering significantly with ability of the amine to act as a base (accept a proton). Useful bases include sodium hydride, potassium hydride, lithium hydride, triethylamine, tri-n-propylamine, and di-isopropyl ethyl amine.
The solvent is chosen so as not to compete with the substrate and to maximize the rate of alkylation. The use of dipolar aprotic solvents such as dimethyl formamide, dimethyl sulfoxide, dimethylacetamide, sulfolane, N-methylpyrrolidione, etc., appears to optimize these attributes. Otherwise, any dipolar aprotic solvent may be selected by the person of ordinary skill so long as the solvent is capable of bringing the reactants into solution. The preferred temperature range for the alkylation process is at or near ambient temperature (25±5° C.). Higher temperatures tend to stimulate competitive side-reactions between the alkylating agent and the tertiary amine catalyst (where the latter is being used).
Yields according to the invention are at least as high as with prior art methods. The high yields complement the other advantages of the inventive method including the facts that it is much safer, more convenient, and economical, and allows for ready synthesis of new compounds.
A preferred embodiment of the inventive alkylation process (which employs the preferred substrate and preferred reagent illustrated above) affords the N,N′ disubstituted barbituric acid depicted as structure V where the R groups are phenyl.
N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid
The alkylation preferably takes place in a solvent which is usually a dipolar aprotic solvent like an N,N′-dialkylamide. However, other types of aprotic solvents may also be employed, so long as they are compatible with the base. This alkylating technique is particularly novel and convenient in that the active alkylating species may also be generated in situ by employing precursor substances without isolation of the sulfonate reagent itself. Thus, dimethoxymethane (structure VI) may be reacted with the mixed anhydride of acetic and methanesulfonic acids (structure VII) and the resulting in situ generated sulfonate ester, methoxymethyl methanesulfonate (structure VIII, which is structure III where R3=H, R4=H, and R5=CH3) may be applied without isolation or purification to the N-alkylation of the barbituric acid.
The following examples are intended to illustrate various embodiments of the invention without limiting its scope.
A. Using a Hindered Tertiary Amine Catalyst
Dimethoxymethane (10.85 g) was added at 0° C. to 19.7 g of acetylmethanesulfonate. The reaction was stirred at 25° C. for 2 hours. The resultant solution was then added gradually over 45 minutes to a mixture of 10 g of 5,5-diphenylbarbituric acid and 13.85 g of N,N-diisopropyl ethyl amine in 60 ml of dry dimethylformamide. The resultant reaction mixture was stirred for about 15 minutes and then diluted with 180 ml of 2 N HCl, followed by 300 ml of ethyl acetate. The phases were separated and the ethyl acetate phase was washed first with 150 ml of saturated aqueous sodium chloride and then with 150 ml of 2N aqueous NaOH. The organic (ethyl acetate) phase was dried over anhydrous sodium sulfate, filtered and concentrated to dryness to give 12.2 g of N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid. Crystalization from 48 ml of toluene afforded 10.5 g of pure product (79.6% yield).
B. Using Triethylamine as Catalyst
By the procedure of example A, using 10.84 g, of triethylamine (in place of 13.85 g of diisopropylethylamine), there resulted 10.62 g of crude alkylated product. Crystallization from 40 ml of toluene afforded 7.6 g (58.5%) of N,N′-bismethoxymethyl 5,5-diphenylbarbituric acid.
C. Using Sodium Hydride as Catalyst
By the procedure of example A, using 3.57 g of sodium hydride (60% dispersion in mineral oil) in place of the amine catalyst, there resulted after crystallization from toluene 5.0 g (38%) of N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid.
D. Using Acetylbenzenesulfonate in place of acetylmethanesulfonate
By the procedure of example A, using 28.55 g of acetylbenzenesulfonate in place of acetylmethanesulfonate (19.7 g), the pure alkylated product resulted in 75.5% yield.
Completion of the reaction may be checked using conventional methods such as by TLC on silica (mobile phase chloroform methanol 98:2). The reaction mixture is diluted with 360 ml of water and extracted with 480 ml of ethyl acetate. The organic layer is separated and washed twice with 150 ml of water. The solvent is removed by distillation under reduced pressure in order to obtain crude product. The crude product may be purified by crystallization from 4 parts of toluene. The mixture is heated to reflux to dissolve and cooled to room temperature. According to HPLC the product of the inventive method has 98-100% purity, and yields of about 60-80% may be expected.
By the procedure of Example 1A, using diethoxymethane (15.42 g) in place of dimethoxymethane (10.85 g), there is obtained a 68% yield of pure N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid.
By the procedure of 1A, using phenytoin (18 g) in place of 5,5-diphenylbarbituric acid (10 g), there is obtained a 70% yield of 3-methoxymethylphenytoin.
By the procedure of 1A, using glutethimide (15.5 g) in place of 5,5-diphenylbarbituric acid (10 g) there is obtained a 65% yield of N-methoxymethylglutethimide.
By the procedure of 1A, using ethosuximide (10 g) in place of 5,5-diphenylbarbituric acid (10 g), there is obtained a 60% yield of N-methoxymethylethosuximide.
The monosubstituted methoxymethyl derivative is obtained by optimizing the procedure of Example 1A to favor monosubstitution, using an excess of NaH and one equivalent of alkylating agent per equivalent of ureide. The monosubstituted product is separated and characterized.
The compounds of examples 2-6 have advantageous pharmaceutical properties over a sustained period of time. They may be used to treat mammals including humans for convulsions, seizures, muscle stiffness, nervous strain or anxiety, by administering an effective amount of the compound in a pharmaceutically acceptable carrier to the patient.
The embodiments illustrated and discussed in this specification are intended only to teach those skilled in the art the best way known to the inventors to make and use the invention. Nothing in this specification should be considered as limiting the scope of the present invention. Modifications and variations of the above-described embodiments of the invention are possible without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described.
Claims (32)
in the presence of a base in an aprotic reaction medium, to provide a corresponding alkylated ureide, wherein R1 and R2 are each either non-cyclic alkyl, aryl, arylalkyl, or R1 and R2 together form a cyclic group having a total of at least 5 atoms each of which is selected from the group consisting of carbon, nitrogen and oxygen, and wherein R3=H, lower alkyl, phenyl, or alkyl substituted phenyl, R4=H, lower alkyl, phenyl, or alkyl substituted phenyl, and R5=lower alkyl, phenyl, or alkyl substituted phenyl.
2. A process of N-alkylation of a ureide comprising:
in the presence of a base and an aprotic solvent, wherein one of R1 and R2 is NH2, NHCOCH3, or non-cyclic alkyl, aryl, arylalkyl, or haloalkyl, and the other of R1 and R2 is non-cyclic alkyl, aryl, arylalkyl, or haloalkyl, or wherein R1 and R2 together form a cyclic group selected from the group consisting of NHCOC(R6)(R7), NHC(R6)(R7), CH2CH2C(R6) (R7), OC(R6)(R7) and CH2C(R6)(R7), wherein R6 and R7, are each either noncyclic alkyl, aryl or arylalkyl, and wherein R3=H, lower alkyl, phenyl, or alkyl substituted phenyl, R4=H, lower alkyl, phenyl, or alkyl substituted phenyl, and R5=lower alkyl, phenyl, or alkyl substituted phenyl, to provide a resultant N-alkoxyalkylated ureide.
3. A process according to claim 2 , wherein the ureide is a 5,5-disubstituted barbituric acid.
4. A process according to claim 2 , wherein the ureide is 5,5-diphenyl barbituric acid, the ester of a sulfonic acid is selected from the group consisting of methoxymethyl methanesulfonate, methoxymethyl ethanesulfonate, methoxymethyl benzenesulfonate, and methoxymethyl p-toluenesulfonate, the base is di-isopropyl ethyl amine, and the resultant ureide is N,N′-bismethoxymethyl-5,5-diphenyl barbituric acid.
5. A process according to claim 2 , wherein the ureide is selected from the group consisting of 5,5-diphenyl barbituric acid, phenytoin, glutethimide, ethosuximide, 5-phenyl-5-ethylbarbituric acid, and 5,5-diethylbarbituric acid.
6. A process according to claim 2 , wherein the ureide is selected from the group consisting of acecarbromal, apronalide, bromisolvalum, capuride, carbromal, ectylurea, hydantoins, glutarimides, oxazolidinediones, succinimides, and barbiturates.
7. A process according to claim 2 , wherein the ester of a sulfonic acid is methoxymethyl methanesulfonate.
8. A process according to claim 2 , wherein the ester of a sulfonic acid is selected from the group consisting of ethoxymethyl methanesulfonate, benzyloxymethyl methanesulfonate, methoxymethyl ethanesulfonate, methoxymethyl benzenesulfonate, methoxymethyl p-toluenesulfonate, methoxylbenzylidene methanesulfonate, and methoxyethylidene methanesulfonate.
9. A process according to claim 2 , wherein the base is non-aqueous with a strength between sodium hydride and a tertiary amine.
10. A process according to claim 2 , wherein the base is a tertiary amine.
11. A process according to claim 2 , wherein the base is selected from the group consisting of sodium hydride, potassium hydride, lithium hydride, triethyl amine tri-n-propylamine, and di-isopropy ethyl amine.
12. A process according to claim 2 , wherein the ester of a sulfonic acid is produced in situ and is combined directly with the ureide without isolating the ester of a sulfonic acid.
13. A process according to claim 2 , further comprising reacting a mixed anhydride of acetic acid and a sulfonic acid with a dialkoxymethane to provide the ester of the sulfonic acid in situ and combined with the ureide without isolating the ester of the sulfonic acid.
14. A process according to claim 2 , wherein the ureide is 5,5-disubstituted barbituric acid, which is converted to its di-anion salt with a strong base, and one equivalent of the ester of a sulfonic acid is added, to provide the corresponding mono-alkylated barbituric acid.
15. A process according to claim 2 , wherein the aprotic reaction medium is a dipolar solvent.
16. A process according to claim 2 , wherein the dipolar solvent is selected from the group consisting of dimethyl formamide, dimethyl sulfoxide, dimethylacetamide, sulfolane, and N-methylpyrrolidione.
17. A process according to claim 3 , wherein the the ureide is 5,5-diphenyl barbituric acid, the ester of a sulfonic acid is selected from the group consisting of methoxymethyl methanesulfonate, ethoxymethyl methanesulfonate, benzyloxymethyl methanesulfonate, methoxymethyl ethanesulfonate, methoxymethyl benzenesulfonate, methoxymethyl p-toluenesulfonate, methoxylbenzylidene methanesulfonate, and methoxyethylidene methanesulfonate, the base is a non-aqueous base selected from a hydride or an amine, and the process further comprises isolating the resultant alkoxyalkylated 5,5-diphenyl-barbituric acid.
18. A process according to claim 17 , wherein the ureide is alkoxyalkylated to an N-mono-alkoxyalkylated 5,5-diphenyl barbituric acid.
19. A process according to claim 18 , wherein the ester is a methoxymethyl ester, the base is very strong and is present in excess, and the isolated compound is N-methoxymethyl-5,5-diphenylbarbituric acid.
20. An alkoxyalkylated ureide compound selected from the group consisting of N-methoxymethyl ethosuximide, and N-methoxymethyl glutethimide, and N-methoxymethyl-5,5-diphenylbarbituric acid .
21. A compound according to claim 20 , wherein the compound is N-methoxymethyl ethosuximide.
22. A compound according to claim 20 , wherein the compound is N-methoxymethyl glutethimide.
23. A compound according to claim 20 , wherein the compound is N-methoxymethyl-5,5-diphenylbarbituric acid.
24. A method of treating a mammal for a condition selected from the group consisting of convulsions, seizures, muscle stiffness, or anxiety comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical agent comprising a compound according to claim 20 .
in the presence of a base in an aprotic reaction medium, to provide a corresponding alkylated ureide, wherein R1 and R2 together form a cyclic group having a total of at least 5 atoms each of which is selected from the group consisting of carbon nitrogen and oxygen, and wherein R3=H, lower alkyl, phenyl, or alkyl substituted phenyl, R4=H, lower alkyl, phenyl, or alkyl substituted phenyl, and R5=lower alkyl, phenyl, or alkyl substituted phenyl.
26. A process for N-alkoxyalkylation of a ureide comprising:
in the presence of a base and an aprotic solvent,
wherein X is O, NH, CH2, CH2—CH2 or C(O)NH, and wherein R6 and R7 are each either noncyclic alkyl, aryl or arylalkyl, and wherein R3=H, lower alkyl, phenyl, or alkyl substituted phenyl, R4=H, lower alkyl, phenyl or alkyl substituted phenyl, and R5=lower alky alkyl, phenyl, or alkyl substituted phenyl, to provide a resultant N-alkoxyalkylated ureide.
27. Isolated N-methoxymethyl- 5,5 -diphenylbarbituric acid.
28. A method of treating a mammal in need of treatment for a condition selected from the group consisting of convulsions, seizures, muscle stiffness, and anxiety, comprising administering to the mammal an effective amount of a pharmaceutical agent comprising N-methoxymethyl- 5,5 -diphenylbarbituric acid.
29. The method of claim 28 , wherein the condition is convulsions.
30. The method of claim 28 , wherein the condition is seizures.
31. The method of claim 28 , wherein the condition is muscle stiffness.
32. The method of claim 28 , wherein the condition is anxiety.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/375,340 USRE38934E1 (en) | 1997-10-02 | 2003-02-27 | Method and reagents for N-alkylating ureides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/942,636 US6093820A (en) | 1997-10-02 | 1997-10-02 | Method and reagents for N-alkylating ureides |
US10/375,340 USRE38934E1 (en) | 1997-10-02 | 2003-02-27 | Method and reagents for N-alkylating ureides |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/942,636 Reissue US6093820A (en) | 1997-10-02 | 1997-10-02 | Method and reagents for N-alkylating ureides |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE38934E1 true USRE38934E1 (en) | 2006-01-10 |
Family
ID=25478386
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/942,636 Ceased US6093820A (en) | 1997-10-02 | 1997-10-02 | Method and reagents for N-alkylating ureides |
US10/073,051 Expired - Fee Related US6664262B2 (en) | 1997-10-02 | 2002-02-12 | N-methoxymethyl-5,5-diphenylbarbituric acid |
US10/375,340 Expired - Lifetime USRE38934E1 (en) | 1997-10-02 | 2003-02-27 | Method and reagents for N-alkylating ureides |
US10/687,712 Expired - Fee Related US6906079B2 (en) | 1997-10-02 | 2003-10-17 | Method and reagents for N-alkylating ureides |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/942,636 Ceased US6093820A (en) | 1997-10-02 | 1997-10-02 | Method and reagents for N-alkylating ureides |
US10/073,051 Expired - Fee Related US6664262B2 (en) | 1997-10-02 | 2002-02-12 | N-methoxymethyl-5,5-diphenylbarbituric acid |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/687,712 Expired - Fee Related US6906079B2 (en) | 1997-10-02 | 2003-10-17 | Method and reagents for N-alkylating ureides |
Country Status (13)
Country | Link |
---|---|
US (4) | US6093820A (en) |
EP (2) | EP1027339B1 (en) |
JP (2) | JP4061018B2 (en) |
CN (2) | CN1193019C (en) |
AT (2) | ATE299500T1 (en) |
AU (1) | AU758506B2 (en) |
CA (1) | CA2304970C (en) |
DE (2) | DE69830860T2 (en) |
DK (2) | DK1027339T3 (en) |
ES (2) | ES2243833T3 (en) |
IL (2) | IL135284A (en) |
PT (2) | PT1027339E (en) |
WO (1) | WO1999018084A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040029902A1 (en) * | 2002-02-01 | 2004-02-12 | Rajinder Singh | 2,4-Pyrimidinediamine compounds and their uses |
US20040224947A1 (en) * | 2000-07-26 | 2004-11-11 | Moros Daniel A. | Non-sedating barbiturate compounds as neuroprotective agents |
US20050234049A1 (en) * | 2003-07-30 | 2005-10-20 | Rajinder Singh | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
US20060035915A1 (en) * | 2000-07-26 | 2006-02-16 | Taro Pharmaceutical Industries, Ltd. | Non-sedating barbituric acid derivatives |
US20060122208A1 (en) * | 2000-07-26 | 2006-06-08 | Daniella Gutman | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
US20060234983A1 (en) * | 2005-01-19 | 2006-10-19 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US20070072886A1 (en) * | 2002-12-11 | 2007-03-29 | Daniel Moros | Method of treating movement disorders using barbituric acid derivatives |
US20080132529A1 (en) * | 2006-11-14 | 2008-06-05 | Avraham Yacobi | Method of improving bioavailability for non-sedating barbiturates |
WO2012058216A2 (en) | 2010-10-27 | 2012-05-03 | The Gillette Company | Composition dispensing device comprising a non-foaming hydrating composition |
WO2013025772A2 (en) | 2011-08-16 | 2013-02-21 | The Gillette Company | Composition dispensing device comprising a moisturizing composition |
WO2015066486A1 (en) | 2013-11-01 | 2015-05-07 | The Gillette Company | Shave care composition for a liquid dispensing razor |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093820A (en) | 1997-10-02 | 2000-07-25 | Taro Pharmaceutical Industries Ltd. | Method and reagents for N-alkylating ureides |
JP2005516052A (en) * | 2002-01-30 | 2005-06-02 | タロ ファーマシューティカル インダストリーズ リミテッド | Non-sedating barbituric acid derivatives |
WO2006003651A2 (en) * | 2004-07-02 | 2006-01-12 | Taro Pharmaceutical Industries, Ltd | A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid |
EP1625848A1 (en) * | 2004-08-10 | 2006-02-15 | Taro Pharmaceuticals North America, Inc. | Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid |
US8853257B2 (en) | 2005-11-21 | 2014-10-07 | Mordechai Sharir | Succinimide derivatives as ocular hypotensive agents |
AU2006314062A1 (en) * | 2005-11-21 | 2007-05-24 | Mordechai Sharir | Succinimide derivatives as ocular hypotensive agents |
US20120278179A1 (en) | 2011-04-28 | 2012-11-01 | Ray Campbell | Systems and methods for deducing user information from input device behavior |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2673205A (en) | 1951-02-13 | 1954-03-23 | Ciba Pharm Prod Inc | 3-disubstituted dioxopiperidines and the manufacture thereof |
DE2622981A1 (en) | 1976-05-21 | 1977-12-08 | Unisearch Ltd | (N)-Haloalkyl nitrogen-contg. heterocyclics prodn. - by reacting (N)-heterocyclics e.g. barbiturates with bis-haloalkyl sulphates, e.g. bis-chloroethyl sulphate |
US4628056A (en) * | 1983-09-14 | 1986-12-09 | Taro Pharmaceutical Industries Ltd. | Novel oxopyrimidine derivatives, pharmaceutical compositions containing them and their use as anticonvulsant, antianxiety and muscle relaxant agents |
DE4028040A1 (en) | 1990-09-05 | 1992-03-12 | Chemie Linz Deutschland | N-Alkylation of urea cpds. - by reacting urea cpd. with alkylating agent in diluent in presence of phase transfer catalyst and solid base |
US6184238B1 (en) | 1996-12-26 | 2001-02-06 | Nikken Chemicals Co., Ltd. | N-hydroxyurea derivative and pharmaceutical composition containing the same |
EP1083172A1 (en) | 1998-05-26 | 2001-03-14 | Rimma Iliinichna Ashkinazi | N-substituted derivatives of 5-oxyiminobarbituric acid |
WO2001079185A1 (en) | 2000-04-18 | 2001-10-25 | Kenneth Curry | Novel amino carboxy alkyl derivatives of barbituric acid |
WO2002007729A1 (en) | 2000-07-26 | 2002-01-31 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
US6372757B1 (en) | 1998-05-08 | 2002-04-16 | Smithkline Beecham P.L.C. | Phenylurea and phenylthio urea derivatives |
US6664262B2 (en) | 1997-10-02 | 2003-12-16 | Taro Pharmaceuticals Industries Ltd. | N-methoxymethyl-5,5-diphenylbarbituric acid |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR204518A1 (en) * | 1973-02-28 | 1976-02-12 | Kendall & Co | PROCEDURE TO PREPARE N-MONO (ALCOXIMETHYL) PHENOBARBITAL |
DE19504623A1 (en) | 1995-02-13 | 1996-08-14 | Bayer Ag | Process for the preparation of N-substituted cyclic imides |
-
1997
- 1997-10-02 US US08/942,636 patent/US6093820A/en not_active Ceased
-
1998
- 1998-10-02 DK DK98949706T patent/DK1027339T3/en active
- 1998-10-02 EP EP98949706A patent/EP1027339B1/en not_active Expired - Lifetime
- 1998-10-02 DK DK03011817T patent/DK1342718T3/en active
- 1998-10-02 ES ES03011817T patent/ES2243833T3/en not_active Expired - Lifetime
- 1998-10-02 IL IL13528498A patent/IL135284A/en not_active IP Right Cessation
- 1998-10-02 JP JP2000514895A patent/JP4061018B2/en not_active Expired - Fee Related
- 1998-10-02 PT PT98949706T patent/PT1027339E/en unknown
- 1998-10-02 CA CA2304970A patent/CA2304970C/en not_active Expired - Fee Related
- 1998-10-02 CN CNB988098342A patent/CN1193019C/en not_active Expired - Fee Related
- 1998-10-02 AU AU95976/98A patent/AU758506B2/en not_active Ceased
- 1998-10-02 DE DE69830860T patent/DE69830860T2/en not_active Expired - Lifetime
- 1998-10-02 AT AT03011817T patent/ATE299500T1/en active
- 1998-10-02 ES ES98949706T patent/ES2214736T3/en not_active Expired - Lifetime
- 1998-10-02 CN CNA2005100026661A patent/CN1699349A/en active Pending
- 1998-10-02 PT PT03011817T patent/PT1342718E/en unknown
- 1998-10-02 EP EP03011817A patent/EP1342718B1/en not_active Expired - Lifetime
- 1998-10-02 AT AT98949706T patent/ATE257153T1/en active
- 1998-10-02 WO PCT/US1998/020665 patent/WO1999018084A1/en active Application Filing
- 1998-10-02 DE DE69820895T patent/DE69820895T2/en not_active Expired - Lifetime
-
2002
- 2002-02-12 US US10/073,051 patent/US6664262B2/en not_active Expired - Fee Related
-
2003
- 2003-02-27 US US10/375,340 patent/USRE38934E1/en not_active Expired - Lifetime
- 2003-10-17 US US10/687,712 patent/US6906079B2/en not_active Expired - Fee Related
-
2004
- 2004-11-07 IL IL16508004A patent/IL165080A0/en unknown
-
2007
- 2007-10-23 JP JP2007275316A patent/JP2008101002A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2673205A (en) | 1951-02-13 | 1954-03-23 | Ciba Pharm Prod Inc | 3-disubstituted dioxopiperidines and the manufacture thereof |
DE2622981A1 (en) | 1976-05-21 | 1977-12-08 | Unisearch Ltd | (N)-Haloalkyl nitrogen-contg. heterocyclics prodn. - by reacting (N)-heterocyclics e.g. barbiturates with bis-haloalkyl sulphates, e.g. bis-chloroethyl sulphate |
US4628056A (en) * | 1983-09-14 | 1986-12-09 | Taro Pharmaceutical Industries Ltd. | Novel oxopyrimidine derivatives, pharmaceutical compositions containing them and their use as anticonvulsant, antianxiety and muscle relaxant agents |
DE4028040A1 (en) | 1990-09-05 | 1992-03-12 | Chemie Linz Deutschland | N-Alkylation of urea cpds. - by reacting urea cpd. with alkylating agent in diluent in presence of phase transfer catalyst and solid base |
US6184238B1 (en) | 1996-12-26 | 2001-02-06 | Nikken Chemicals Co., Ltd. | N-hydroxyurea derivative and pharmaceutical composition containing the same |
US6664262B2 (en) | 1997-10-02 | 2003-12-16 | Taro Pharmaceuticals Industries Ltd. | N-methoxymethyl-5,5-diphenylbarbituric acid |
US6372757B1 (en) | 1998-05-08 | 2002-04-16 | Smithkline Beecham P.L.C. | Phenylurea and phenylthio urea derivatives |
EP1083172A1 (en) | 1998-05-26 | 2001-03-14 | Rimma Iliinichna Ashkinazi | N-substituted derivatives of 5-oxyiminobarbituric acid |
WO2001079185A1 (en) | 2000-04-18 | 2001-10-25 | Kenneth Curry | Novel amino carboxy alkyl derivatives of barbituric acid |
WO2002007729A1 (en) | 2000-07-26 | 2002-01-31 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
Non-Patent Citations (24)
Title |
---|
Aldrich Chemical Catalog, 1990-1991, p. 303. * |
Bhardwaj et al.: "Pentobarbital Inhibits extracellular release of dopamine in the Ischemic Striatum"; Journal of Neural Transmission [GenSect] (1990) 82; pp. 111-117. |
Casara et al.: "Synthesis of Acid Stable Fluorinated Acyclonucleosides as Potential Antiviral Agents"; Tetrahedron Letters, vol. 32, No. 31, pp. 3823-3826, 1991. |
Foye, "Principles of Medicinal Chemistry", 3rd ed., 1990, pp. 164, 179. * |
Groth et al., EP-726252, (1996) (Abstract only). * |
JP Gesson, JC Jacquesy, D. Rambaud, A practical method for N-alkylation of succinimide and glutarimide, Bulletin De La Societe Chimique De France, vol. 129, No. 3, 1992, pp. 227-231. * |
Karger et al., "Methoxymethyl Methanesulfonate, N Novel Active Oxyakylating Agent", Journal of the American Chemical Society, 91:5663 (1969). * |
Loudon et al: "Organic Chemistry"; Addison-Wesley (1984), pp. 617, 721-722, 1061-1064, 1086-1088, 1194. |
Masuda et al.: "Relationships Between Plasma Concentrations of Diphenythydantoin, Phenobarbital, Carbamazepine, and 3-Sulfamoylmethyl-1,2-Benzisoxazole (AD-810), a New Anticonvulsant Agent, and Their Anticonvulsant or Neurotoxic Effects in Experimental Animals"; Epilepsia, vol. 20, December 1979, pp. 623-633. |
McElvain: "5,5-Diphenylbarbituric Acid"; vol. 57, pp. 1303-1304, (1935). |
P. Casara et al., Synthesis of acid stable fluorinated acylnacleosides, vol. 32, No. 31, 1991, pp. 3823-3826. * |
Raines, et al., "A Comparison of the Anticonvulsant, Neurotoxic and Lethal Effects of Diphenylbarbituric Acid Phenobarbital and Diphenylhydantoin in the Mouse," Journal of Pharmacology and Experimental Therapeutics, 186:315-322 (1973). |
Raines, et al., "Conversion of Dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Dog," The FASEB J., 13(4):A475,Ansract 394.2 (1999). |
Raines, et al., "Conversion of Dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Rat," The FASEB J., 10:A-155, Abstract 895 (1996). |
Raines, et al., "Differential Selectivity of Several Barbiturates on Experimental Seizures and Neurotoxicity in the Mouse," Epilepsia, 20:105-113 (1979). |
Raines, et al., "The Effects of 5,5-Diphenylbarbituric Acid on Experimental Seizures in Rats: Correlation Between Plasma and Brain Concentrations and Anticonvulsant Activity," Epilepsia,16:575-581 (1975). |
Raines, et al.,"Serum and Brain Levels of 5-5-Diphenylbarbituric Acid (DPB) After Administration of dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) in the Rat," Epilepsia, 37:Supp. 5, p. 23, Abstract 1.84 (1996). |
Samour et al. DE1939787, (1970) (Abstract only). * |
Samour et al.: "Anticonvulsants. 1, Alkoxymethyl Derivatives of Barbiturates and Diphenylhydantoin"; Journal of Medicinal Chemistry, 1971, vol. 14, No. 3 pp. 187-189. |
Sircar, "CLXXIII.-The Influence of Groups and Associated Rings on the Stability of Certain Heterocyclic Systems. Part II. The Substituted Succinimides"; Journal of the Chemical Society, May 1927, pp. 1252-1258. |
Susumu Kamata, Nobuhiro Haga, Takeaki Matsui and Wataru Nagata, Studies of Antitumor-Active 5-Fluorouracil Derivatives. I. Systhesis of N-Phthalidyl 5-Fluorouracil Derivatives, Chemical And Pharmaceutical Bulletin, vol. 33, No. 8, 1985, pp. 3160-3175. * |
Tagmann et al; Helv. Chim. Acta 35, 1541-1549 (1952). |
Thacker et al., "A Method for Determination of 5,5-Diphenylbarbituric Acid and Separation from 1,3-Dimethoxymethyl-5,5-Diphenylbarbituric Acid in Plasma by High Performance Liquid Chromatography," Journal of Chromatography B, 710:149-155 (1998). |
The Merck Index; An Encyclopedia of Chemicals, Drugs, and Biologicals; Tenth Edition, Published by Merck & Co., Inc., Rahway, NJ, USA, 1983, p. 544, (entry 3697). |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7683071B2 (en) | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
US20040224947A1 (en) * | 2000-07-26 | 2004-11-11 | Moros Daniel A. | Non-sedating barbiturate compounds as neuroprotective agents |
US8158639B2 (en) | 2000-07-26 | 2012-04-17 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
US20060035915A1 (en) * | 2000-07-26 | 2006-02-16 | Taro Pharmaceutical Industries, Ltd. | Non-sedating barbituric acid derivatives |
US20060122208A1 (en) * | 2000-07-26 | 2006-06-08 | Daniella Gutman | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
US20060205747A1 (en) * | 2000-07-26 | 2006-09-14 | Moros Daniel A | Non-sedating barbiturate compounds as neuroprotective agents |
US8076346B2 (en) | 2000-07-26 | 2011-12-13 | Taro Pharamaceutical Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
US20100144769A1 (en) * | 2000-07-26 | 2010-06-10 | Taro Pharmaceutical Industries Limited | Composition and method for improved bioavailability and enhanced brain delivery of 5 5-diphenyl barbituric acid |
US7723346B2 (en) | 2000-07-26 | 2010-05-25 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
US20110144330A1 (en) * | 2002-02-01 | 2011-06-16 | Rigel Pharmaceuticals, Inc. | 2,4-Pyrimidinediamine Compounds and their Uses |
US9346765B2 (en) | 2002-02-01 | 2016-05-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US20040029902A1 (en) * | 2002-02-01 | 2004-02-12 | Rajinder Singh | 2,4-Pyrimidinediamine compounds and their uses |
US9913842B2 (en) | 2002-02-01 | 2018-03-13 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7557210B2 (en) | 2002-02-01 | 2009-07-07 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9416112B2 (en) | 2002-02-01 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US8835430B2 (en) | 2002-02-01 | 2014-09-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US10682350B2 (en) | 2002-02-01 | 2020-06-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US20070225321A1 (en) * | 2002-02-01 | 2007-09-27 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9018204B1 (en) | 2002-02-01 | 2015-04-28 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US10709703B2 (en) | 2002-02-01 | 2020-07-14 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7906644B2 (en) | 2002-02-01 | 2011-03-15 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US8314115B2 (en) | 2002-12-11 | 2012-11-20 | Taro Pharmaceutical Industries Limited | Method of treating movement disorders using barbituric acid derivatives |
US7776871B2 (en) | 2002-12-11 | 2010-08-17 | Taro Pharmaceutical Industries Ltd. | Method of treating movement disorders using barbituric acid derivatives |
US20070072886A1 (en) * | 2002-12-11 | 2007-03-29 | Daniel Moros | Method of treating movement disorders using barbituric acid derivatives |
US20080312438A1 (en) * | 2003-07-30 | 2008-12-18 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US20050234049A1 (en) * | 2003-07-30 | 2005-10-20 | Rajinder Singh | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
US7582648B2 (en) | 2003-07-30 | 2009-09-01 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US20090124580A1 (en) * | 2005-01-19 | 2009-05-14 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US7563892B1 (en) | 2005-01-19 | 2009-07-21 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4 pyrimidinediamine compounds and their uses |
US20060234983A1 (en) * | 2005-01-19 | 2006-10-19 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8476263B2 (en) | 2005-01-19 | 2013-07-02 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8785437B2 (en) | 2005-01-19 | 2014-07-22 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8211889B2 (en) | 2005-01-19 | 2012-07-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US10577381B2 (en) | 2005-01-19 | 2020-03-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US7538108B2 (en) | 2005-01-19 | 2009-05-26 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US9266912B2 (en) | 2005-01-19 | 2016-02-23 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US7989448B2 (en) | 2005-01-19 | 2011-08-02 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8211888B2 (en) | 2005-01-19 | 2012-07-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US9532998B2 (en) | 2005-01-19 | 2017-01-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US20080132529A1 (en) * | 2006-11-14 | 2008-06-05 | Avraham Yacobi | Method of improving bioavailability for non-sedating barbiturates |
WO2012058216A2 (en) | 2010-10-27 | 2012-05-03 | The Gillette Company | Composition dispensing device comprising a non-foaming hydrating composition |
WO2013025772A2 (en) | 2011-08-16 | 2013-02-21 | The Gillette Company | Composition dispensing device comprising a moisturizing composition |
WO2015066486A1 (en) | 2013-11-01 | 2015-05-07 | The Gillette Company | Shave care composition for a liquid dispensing razor |
Also Published As
Publication number | Publication date |
---|---|
DE69820895D1 (en) | 2004-02-05 |
US6906079B2 (en) | 2005-06-14 |
EP1342718A1 (en) | 2003-09-10 |
IL135284A (en) | 2005-11-20 |
JP2008101002A (en) | 2008-05-01 |
US20030018080A1 (en) | 2003-01-23 |
DK1342718T3 (en) | 2005-09-26 |
EP1027339B1 (en) | 2004-01-02 |
IL165080A0 (en) | 2005-12-18 |
DE69820895T2 (en) | 2004-10-28 |
CN1273581A (en) | 2000-11-15 |
JP4061018B2 (en) | 2008-03-12 |
DE69830860D1 (en) | 2005-08-18 |
PT1342718E (en) | 2005-11-30 |
PT1027339E (en) | 2004-05-31 |
AU9597698A (en) | 1999-04-27 |
CN1699349A (en) | 2005-11-23 |
AU758506B2 (en) | 2003-03-20 |
EP1027339A1 (en) | 2000-08-16 |
CA2304970C (en) | 2010-07-13 |
US20040167358A1 (en) | 2004-08-26 |
CN1193019C (en) | 2005-03-16 |
ATE299500T1 (en) | 2005-07-15 |
CA2304970A1 (en) | 1999-04-15 |
ES2243833T3 (en) | 2005-12-01 |
EP1342718B1 (en) | 2005-07-13 |
ES2214736T3 (en) | 2004-09-16 |
JP2001519334A (en) | 2001-10-23 |
WO1999018084A1 (en) | 1999-04-15 |
DK1027339T3 (en) | 2004-05-03 |
DE69830860T2 (en) | 2006-04-27 |
ATE257153T1 (en) | 2004-01-15 |
US6664262B2 (en) | 2003-12-16 |
US6093820A (en) | 2000-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE38934E1 (en) | Method and reagents for N-alkylating ureides | |
US6624324B2 (en) | Process for producing optically active hemiesters | |
CZ20031692A3 (en) | Process for preparing sulfonamide-substituted imidazotriazinones | |
US6307053B1 (en) | Process for preparing imidacloprid | |
SK158094A3 (en) | Method of production 1-(alkoxymethyl) pyrole compounds | |
GB2106499A (en) | Method for making benzoylphenylureas | |
CA1271769A (en) | 4-alkoxy-3-pyrrolin-2-on-1-yl acetic acid alkyl esters and their production | |
US4242347A (en) | Hypotensive indolylalkylpiperidyl guanidines and isoureas | |
US3880871A (en) | Isothiocyanophenyl substituted imidazoles | |
US5486617A (en) | Process for the preparation of 2-substituted 5-chloroimidazole-4-carbaldehydes | |
Dell'Erba et al. | Reactions of arylazosulfones with the conjugate bases of (tert-butoxycarbonyl) methyl and tosylmethyl isocyanide. Synthesis of substituted 1-arylimidazoles | |
US4480130A (en) | Preparation of ortho-(alkylthiomethyl) anilines by catalytic sulfilimine rearrangement | |
CA1274850A (en) | .alpha.-CHLOROKETONE DERIVATIVE AND PROCESS FOR PREPARATION THEREOF | |
JP3716435B2 (en) | Process for producing 2-substituted-5-chloroimidazole-4-carbaldehyde | |
KR810001892B1 (en) | Process for preparing phenylethylamines | |
GB1561516A (en) | 1-(azacylic aralkoxyphenyl) - 2 - or - 3-(bis -arylalkylamino alkanes process for their manufacture and pharmaceutical preparation containint them | |
US6964963B2 (en) | Preparation of 4-amino-1-naphthol ethers | |
US7365210B2 (en) | Method for the production of chiral imidazolidin-2-ones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 12 |